Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome
NCT ID: NCT02022228
Last Updated: 2013-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2012-07-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH) level post trigger with single injection of GnRH agonist, which might be related to the shorter duration and lower amount of LH induced by GnRH agonist.
Our aim is to study dual trigger with GnRH agonist and human chorionic gonadotropin (hCG) for preventing OHSS and maintaining clinical outcome in high risk patients who receive controlled ovarian stimulation in GnRH antagonist protocol.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.2mg triptorelin and 500 IU hCG
Patients were triggered with 0.2mg triptorelin and 500 IU hCG
triptorelin
0.2 mg triptorelin, ih
hCG
500IU hCG, im
0.2mg triptorelin and 1000 IU hCG
Patients were triggered with 0.2mg triptorelin and 1000 IU hCG
triptorelin
0.2 mg triptorelin, ih
hCG
1000 IU hCG, im
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
triptorelin
0.2 mg triptorelin, ih
hCG
1000 IU hCG, im
hCG
500IU hCG, im
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with polycystic ovarian morphology on ultrasound
* patients who previously experienced an ovarian stimulation cycle, with a high response to gonadotrophins
Exclusion Criteria
* patients with past ovarian surgery
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Natural Science Foundation of China
OTHER_GOV
Comprehensive Strategic Cooperation Project of Guangdong Province and Chinese Academy of Science
OTHER
Guangzhou Science and Technology Program key projects
OTHER
National Key Basic Research Development Plan of China
UNKNOWN
Chenshiling
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chenshiling
Professor, M.D., Ph.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shi-Ling Chen, M.D., Ph.D.
Role: STUDY_CHAIR
Nanfang Hospital, Southern Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Shi-Ling Chen, M.D., Ph.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dual Trigger
Identifier Type: -
Identifier Source: org_study_id